CBS 2019
CBSMD教育中心
English

充血性心力衰竭

科研文章

荐读文献

A randomized controlled trial to evaluate the safety and efficacy of cardiac contractility modulation in patients with systolic heart failure: rationale, design, and baseline patient characteristics. Reduced Apolipoprotein M and Adverse Outcomes Across the Spectrum of Human Heart Failure The Future of Biomarker-Guided Therapy for Heart Failure After the Guiding Evidence-Based Therapy Using Biomarker Intensified Treatment in Heart Failure (GUIDE-IT) Study Heart Failure With Improved Ejection Fraction-Is it Possible to Escape One’s Past? INTERMACS Profiles and Outcomes Among Non–Inotrope-Dependent Outpatients With Heart Failure and Reduced Ejection Fraction Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes Prior Pacemaker Implantation and Clinical Outcomes in Patients With Heart Failure and Preserved Ejection Fraction Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL 2 Study The Evolution of β-Blockers in Coronary Artery Disease and Heart Failure (Part 1/5) Noninvasive Imaging for the Evaluation of Diastolic Function: Promises Fulfilled

Recommandation Statement2019 Jun 6:CIR0000000000000691.

JOURNAL:Circulation. Article Link

Type 2 Diabetes Mellitus and Heart Failure: A Scientific Statement From the American Heart Association and the Heart Failure Society of America

Dunlay SM, Givertz MM, American Heart Association Heart Failure and Transplantation Committee of the Council on Clinical Cardiology; Council on Cardiovascular and Stroke Nursing; and the Heart Failure Society of America. Keywords: AHA Scientific Statement; diabetes mellitus, type 2; drug therapy; heart failure; lifestyle; risk factors

FULL TEXT PDF